Rigel Pharmaceuticals INC Form 4 insider transactions
NASDAQ
Rigel Pharmaceuticals CEO, Raul R. Rodriguez, exercised stock options for 30,000 shares after a performance-based vesting condition was met.
NASDAQ
Form 4: Rigel Pharmaceuticals Executive Exercises Stock Options After Performance Milestone Achieved
Rigel Pharmaceuticals' EVP and Chief Financial Officer, Dean L. Schorno, exercised stock options for 6,250 shares after a performance-based vesting condition was met.
NASDAQ
Form 4: Rigel Pharmaceuticals CEO Raul Rodriguez Reports Stock Option Grant After Performance Metric Met
CEO Raul Rodriguez reports the grant of a stock option for 32,500 shares of Rigel Pharmaceuticals common stock after a performance-based condition was satisfied on August 30, 2024.
NASDAQ
Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals, acquired 10,000 shares of common stock through a stock option award after a performance metric was met.
NASDAQ
Director Jane Wasman reports acquisition of Rigel Pharmaceuticals stock and options, signaling potential confidence in the company's future.
NASDAQ
Form 4: Rigel Pharmaceuticals Director Walter H. Moos Reports Acquisition of Shares and Stock Options
Director Walter H. Moos reports acquisition of Rigel Pharmaceuticals shares and stock options on May 25, 2024.
NASDAQ
Director Anthony Gregg Lapointe reports acquisition of Rigel Pharmaceuticals stock and options on May 25, 2024.
NASDAQ
Form 4: Rigel Pharmaceuticals Director Brian L. Kotzin Reports Acquisition and Disposal of Securities
Director Brian L. Kotzin reports acquisition of 25,000 shares of common stock and disposal of 100,000 shares, along with acquisition of options to buy 30,000 shares, in Rigel Pharmaceuticals.
NASDAQ
Alison L. Hannah, a director at Rigel Pharmaceuticals, acquired 25,000 shares of common stock and options for 30,000 shares on May 25, 2024.
NASDAQ
Form 4: Rigel Pharmaceuticals Director Ali-Jackson Kamil Reports Acquisition of Shares and Stock Options
Director Ali-Jackson Kamil reports acquisition of 25,000 common stock shares and 30,000 stock options in Rigel Pharmaceuticals.
NASDAQ
Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals, reports the acquisition of stock options.
NASDAQ
Dean Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals, reports the acquisition of stock options due to the satisfaction of performance-based conditions.
NASDAQ
David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals, reports the acquisition of stock options due to the satisfaction of performance-based conditions.
NASDAQ
Rigel Pharmaceuticals' CEO, Raul Rodriguez, received stock options for 600,000 shares after performance-based conditions were met on February 28, 2024.
NASDAQ
Raymond Furey, EVP, GC, CCO & Corp Sec of Rigel Pharmaceuticals, reports the acquisition of stock options after performance-based conditions were satisfied on February 28, 2024.